YOLFTbeta
Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

ARQT · NASDAQ · Healthcare / Biotechnology

28.26USD+0.73 (+2.65%)

Price History

Full chart

Market Stats

Previous Close27.53
Open27.50
Day Range27.06 – 28.33
52-Week Range19.30 – 34.80
Volume849.83K
Market Cap3.48B
P/E (TTM)125.14
Forward P/E31.85
EPS0.22
Dividend Yield0.00%
Beta1.63
50-Day Avg27.37
200-Day Avg25.36

About

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Todd Franklin Watanabe M.A.
  • Employees354
  • Headquarters3027 Townsgate Road, Westlake Village, CA, United States, 91361, USA
  • Websitehttps://www.arcutis.com

Leadership

  • Mr. Todd Franklin Watanabe M.A.President, CEO & Director · b. 1968
  • Dr. Bhaskar Chaudhuri Ph.D.Co-Founder & Director Emeritus · b. 1955
  • Ms. Latha VairavanSenior VP & Chief Financial Officer · b. 1978
  • Mr. Masaru Matsuda Esq., J.D.Executive VP, Chief Legal Officer & Corporate Secretary · b. 1971
  • Dr. Patrick E. Burnett M.D., Ph.D.Executive VP & Chief Medical Officer · b. 1972
  • Mr. Brian SchoelkopfHead of Investor Relations
  • Mr. Steve AriasVice President of Compliance & Privacy
  • Ms. Amanda SheldonHead of Corporate Communications
  • Ms. Aleen HosdaghianVice President of Marketing
  • Mr. Todd TuckerSenior VP & Chief Human Resources Officer

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000003.69M59.61M196.54M376.07M
Growth (%)------+1517.09%+229.74%+91.34%
Cost of Revenue--195.00K455.00K763.00K754.00K4.99M19.13M36.70M
Gross Profit---195.00K-455.00K-763.00K2.93M54.62M177.41M339.38M
Gross Margin-----79.54%91.63%90.27%90.24%
Operating Expense--42.94M136.19M205.77M304.56M295.72M305.81M351.60M
Operating Income-4.11M-19.73M-43.13M-136.65M-206.53M-301.63M-241.10M-128.40M-12.23M
Operating Margin------8183.04%-404.49%-65.33%-3.25%
EBITDA-4.11M-19.25M-41.80M-135.56M-206.07M-294.87M-228.56M-109.63M1.78M
EBITDA Margin------7999.78%-383.46%-55.78%0.47%
Net Income-4.98M-19.25M-42.00M-135.68M-205.90M-311.46M-262.14M-140.04M-16.14M
Net Income Margin------8449.76%-439.79%-71.25%-4.29%
R&D3.41M17.94M36.52M115.31M145.56M182.44M110.58M76.42M77.05M
R&D as % of Total Revenue-----4949.40%185.51%38.88%20.49%
Interest Expense0000454.00K15.65M29.71M27.17M12.08M
Interest Expense % of Total Revenue-----424.63%49.85%13.82%3.21%

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.82M51.10M107.01M298.27M408.15M449.27M341.37M348.89M432.97M
Total Liabilities8.81M75.08M5.55M27.65M110.47M239.69M252.70M191.35M243.49M
Total Equity-4.99M-23.99M101.46M270.62M297.68M209.58M88.67M157.54M189.48M
Cash3.42M39.39M63.34M65.08M97.99M53.64M88.40M71.33M42.91M
Total Debt966.00K-307.00K4.96M77.56M202.54M205.92M110.58M6.27M
Net Debt-2.45M-39.39M-63.03M-60.12M-20.43M148.90M117.52M39.25M-36.64M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.77M-14.09M-42.84M-113.03M-174.63M-257.71M-247.06M-112.16M-5.63M
Investing Cash Flow-11.53M-11.53M-26.32M-181.82M-75.95M-87.20M180.23M28.82M-30.25M
Financing Cash Flow7.12M61.59M93.10M298.14M281.95M301.80M101.32M66.20M6.97M
Capital Expenditure295.00K295.00K295.00K321.00K995.00K23.28M428.00K143.00K686.00K
Free Cash Flow-3.77M-14.09M-43.13M-113.35M-175.62M-281.00M-247.49M-112.30M-6.31M
Dividends Paid----72.35M122.81M---
FCF to OCF100.00%100.00%100.69%100.28%100.57%109.03%100.17%100.13%112.20%
Dividend Paid to FCF-----41.20%-43.71%---

Earnings

Report DateSep 9, 2019Nov 27, 2019Mar 18, 2020May 12, 2020Aug 11, 2020Nov 5, 2020Feb 16, 2021May 4, 2021Aug 5, 2021Nov 4, 2021Feb 22, 2022May 5, 2022Aug 4, 2022Nov 8, 2022Feb 28, 2023May 9, 2023Aug 8, 2023Nov 3, 2023Feb 27, 2024May 14, 2024Aug 14, 2024Nov 6, 2024Feb 25, 2025May 6, 2025Aug 6, 2025Oct 28, 2025Feb 26, 2026May 6, 2026Aug 5, 2026Oct 27, 2026Nov 4, 2026Feb 24, 2027
EPS Estimate--7.60-9.21-0.85-0.84-0.90-0.86-0.97-0.93-1.19-1.49-1.52-1.42-1.75-1.42-1.26-1.25-0.91-0.80-0.73-0.53-0.42-0.26-0.21-0.16-0.090.09-0.060.090.170.170.21
EPS Actual-0.17-7.60-6.18-1.15-0.94-1.01-0.79-0.76-0.84-1.14-1.42-1.27-1.31-1.89-1.18-1.31-1.16-0.73-0.72-0.32-0.42-0.33-0.09-0.20-0.130.060.13-0.090.11-0.06-
Surprise-0.00%32.90%-35.29%-11.90%-12.22%8.14%21.65%9.68%4.20%4.70%16.45%7.75%-8.00%16.90%-3.97%7.20%19.78%10.00%56.16%20.75%21.43%65.95%4.76%18.75%166.67%46.73%-50.00%22.22%--64.71%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap3.48B
Enterprise Value3.44B
Trailing P/E125.14
Forward P/E31.85
Price / Sales6.84
Price / Book14.70
EPS0.22
Book Value1.94
Revenue (TTM)508.68M
Gross Profit (TTM)463.81M
EBITDA37.41M
Profit Margin5.88%
Operating Margin6.91%
Return on Equity14.88%
Return on Assets4.91%
Shares Outstanding126.46M
Shares Float94.56M
Beta1.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 40.38
  • Strong Buy
    5
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
113.83%
Insiders
1.80%
Retail / Other
0.00%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    12.44M9.89%
  • BlackRock Inc
    10.55M8.39%
  • Frazier Life Sciences Management, L.P.
    9.87M7.86%
  • Rubric Capital Management LP
    8.27M6.58%
  • Polar Capital Holdings PLC
    6.61M5.26%
  • State Street Corp
    5.82M4.63%
  • Vanguard Capital Management, LLC
    4.99M3.97%
  • Morgan Stanley - Brokerage Accounts
    4.45M3.54%
  • Jennison Associates LLC
    4.22M3.36%
  • D. E. Shaw & Co LP
    3.95M3.14%
  • UBS Group AG
    3.33M2.65%
  • Bank of America Corp
    2.99M2.38%
  • Geode Capital Management, LLC
    2.98M2.37%
  • Vanguard Portfolio Management, LLC
    2.43M1.93%
  • Orbimed Advisors LLC
    2.04M1.62%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    6.88M5.44%
  • Polar Capital Biotech S Inc
    6.26M4.95%
  • Vanguard MStar Total Stk Mkt Idx Invest
    3.59M2.84%
  • State Street® SPDR® S&P® Biotech ETF
    3.24M2.56%
  • iShares Russell 2000 ETF
    2.90M2.29%